NCT05126329View on ClinicalTrials.gov

Pharmacokinetics of Amcenestrant in Female Hepatic Impaired Participants as Compared to Participants With Normal Hepatic Function

PHASE1TerminatedINTERVENTIONAL

Enrollment

13

Participants

Timeline

Start Date

November 15, 2021

Primary Completion Date

May 16, 2022

Study Completion Date

May 16, 2022

Conditions

Hepatic Function Abnormal

Interventions

DRUG

amcenestrant

tablet for oral use

Trial Locations (3)

24105

Investigational Site Number :2760001, Kiel

28644

Investigational site number :4100002, Cheongju-si

03080

Investigational Site Number :4100001, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Sanofi

INDUSTRY

NCT05126329 - Pharmacokinetics of Amcenestrant in Female Hepatic Impaired Participants as Compared to Participants With Normal Hepatic Function | Biotech Hunter | Biotech Hunter